<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Malar J</journal-id><journal-title>Malaria Journal</journal-title><issn pub-type="epub">1475-2875</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1475-2875-8-43</article-id><article-id pub-id-type="pmid">19284648</article-id><article-id pub-id-type="doi">10.1186/1475-2875-8-43</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Fc&#x003b3;RIIa (CD32) polymorphism and anti-malarial IgG subclass pattern among Fulani and sympatric ethnic groups living in eastern Sudan</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Nasr</surname><given-names>Amre</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>amre@imun.su.se</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Iriemenam</surname><given-names>Nnaemeka C</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>Nnaemeka.Iriemenam@imun.su.se</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Giha</surname><given-names>Hayder A</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>Giha-gehaha2002@yahoo.com</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Balogun</surname><given-names>Halima A</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>halima@imun.su.se</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Anders</surname><given-names>Robin F</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>Anders-r.anders@latrobe.edu.au</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Troye-Blomberg</surname><given-names>Marita</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>marita@imun.su.se</email></contrib><contrib id="A7" contrib-type="author"><name><surname>ElGhazali</surname><given-names>Gehad</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I7">7</xref><email>gelghazali@kfmc.med.sa</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Berzins</surname><given-names>Klavs</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>klavs@imun.su.se</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Microbiology and Molecular-Biology, Faculty of Science and Technology and Al-Neelain Research Centre, Faculty of Medicine, Al-Neelain University, PO Box 12702, Khartoum, Sudan</aff><aff id="I2"><label>2</label>Department of Immunology, Wenner-Gren Institute, Stockholm University, SE 10691 Stockholm, Svante Arrhenius v&#x000e4;g 16, SE-10 691 Stockholm, Sweden</aff><aff id="I3"><label>3</label>Department of Medical Microbiology and Parasitology, College of Medicine of the University of Lagos, Idi-araba, PMB 12003 Lagos, Nigeria</aff><aff id="I4"><label>4</label>Department of Biochemistry, Faculty of Medicine, University of Khartoum, PO Box 102 Khartoum, Sudan</aff><aff id="I5"><label>5</label>Department of Medical Biochemistry, Faculty of Medicine and Medical Sciences, Arabian Gulf University, PO Box 26671 Manama, Bahrain</aff><aff id="I6"><label>6</label>Department of Biochemistry, La Trobe University, Victoria 3086, Australia</aff><aff id="I7"><label>7</label>Department of Clinical Immunology, Pathology and Clinical Laboratory Medicine, Faculty of Medicine, King Fahad Medical City, Riyadh, Saudi Arabia</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>13</day><month>3</month><year>2009</year></pub-date><volume>8</volume><fpage>43</fpage><lpage>43</lpage><ext-link ext-link-type="uri" xlink:href="http://www.malariajournal.com/content/8/1/43"/><history><date date-type="received"><day>25</day><month>7</month><year>2008</year></date><date date-type="accepted"><day>13</day><month>3</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Nasr et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Nasr et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Nasr Amre amre@imun.su.se </dc:author><dc:title> Fc&#x003b3;RIIa (CD32) polymorphism and anti-malarial IgG subclass pattern among Fulani and sympatric ethnic groups living in eastern Sudan </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Malaria Journal 8(1): 43-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1475-2875(2009)8:1&#x0003c;43&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1475-2875</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>A SNP at position 131, in the Fc&#x003b3;RIIa gene, affects the binding of the different IgG subclasses and may influence the clinical variation seen in patients with falciparum malaria. This study confirms and extends previous findings, analysing the Fc&#x003b3;RIIa (CD32) polymorphism in relation to the IgG subclass distribution seen among two sympatric tribes living in eastern Sudan, characterized by marked differences in susceptibility to <italic>Plasmodium falciparum </italic>malaria.</p></sec><sec sec-type="methods"><title>Methods</title><p>Two hundred and fifty Fulani subjects living in an area of meso-endemic <italic>P. falciparum </italic>malaria infection were genotyped for the Fc&#x003b3;RIIa-131 polymorphism. For comparison, 101 non-Fulani donors &#x02013; (Masaleit, Hausa and Four) &#x02013; living in the same study area, were genotyped. The levels of plasma antibodies (IgG and subclasses) to four malaria antigens (AMA-1, MSP 2 &#x02013; 3D7 &#x00026; FC27, Pf332-C231) were measured using indirect enzyme-linked immunosorbent assays.</p></sec><sec><title>Results</title><p>The Fc&#x003b3;RIIa-H/H131 genotype was found to be significantly more prevalent in the Fulani as compared to the non-Fulani ethnic groups (36.0% for Fulani versus 17.8% for non-Fulani, adjusted OR 3.10, 95% CI 1.61&#x02013;5.97, P value &#x0003c; 0.001). The Fulani showed lower anti-malarial IgG1 and IgG3 antibody levels as compared to the non-Fulani and higher levels of IgG2 antibodies.</p></sec><sec><title>Conclusion</title><p>The Fc&#x003b3;RIIa-H/H131 genotype and H131 allele is at higher frequency in the Fulani ethnic group. The H/H131 genotype was consistently associated with higher levels of anti-malarial IgG2 and IgG3 antibodies, while the R/R131 genotype was associated with higher levels of IgG1 antibodies.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>One of the most common causes of morbidity and mortality in African children is <italic>Plasmodium falciparum </italic>malaria [<xref ref-type="bibr" rid="B1">1</xref>]. For the last 10 years field studies have been carried out in Daraweesh village in eastern Sudan, aimed at understanding the population dynamics and human immune responses to malaria infections in an area of seasonal and unstable malaria transmission. Studies in Daraweesh have demonstrated that a significant proportion of the population harbours asymptomatic infections detectable by a rise in anti-malarial antibody titres during the transmission season [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Naturally acquired antibodies are important for protection against asexual blood stages of malaria, as shown by passive transfer of immunoglobulin gamma (IgG) from African malaria-immune adults to Thai malaria-na&#x000ef;ve patients [<xref ref-type="bibr" rid="B5">5</xref>]. Fc&#x003b3;RIIa, one of three receptors for human IgG, is expressed on the surface of all types of cells of the immune system. Fc&#x003b3;RIIa is a low-affinity receptor for monomeric IgG, but binds IgG immune complexes efficiently [<xref ref-type="bibr" rid="B6">6</xref>]. Fc&#x003b3;RIIa is believed to play a major role in eliciting monocyte and macrophage-mediated effector responses against blood-stage malaria parasites. A single nucleotide polymorphism (SNP) G/A, causes an arginine (R) to be replaced with histidine (H) at position 131, defines two allotypes, which differ in their avidity for complexed human IgG2 and IgG3 [<xref ref-type="bibr" rid="B7">7</xref>]. The H131 receptor is high-binding for IgG2, while the R131 receptor is low-binding for this subclass. IgG2 is a poor activator of the classical complement pathway, and since Fc&#x003b3;RIIa-H131 is essential for handling IgG2 immune complexes therefore this SNP might have an impact on the outcome of the immune response to <italic>P. falciparum </italic>[<xref ref-type="bibr" rid="B6">6</xref>].</p><p>Previous studies involving the Fulani ethnic group in Burkina Faso and Mali have shown that these individuals are less affected by clinical malaria than individuals from other sympatric ethnic groups [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. In addition, the Fulani in Sudan were significantly less parasitized than the individuals of sympatric non-Fulani ethnic groups [<xref ref-type="bibr" rid="B14">14</xref>], corroborating the results previously obtained in Burkina Faso and Mali [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. The lower susceptibility to <italic>P. falciparum </italic>malaria seen in the Fulani could, however, not be explained by gene polymorphisms previously associated with malaria resistance, i.e. HbS, HbC, alpha-thal, G6PD and HLA [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. In a longitudinal study of a Fulani population resident in eastern Sudan, an unexpected variation was seen regarding individual disease susceptibility and outbreak severity [<xref ref-type="bibr" rid="B16">16</xref>]. In this population, it was recently shown that Fc&#x003b3;RIIa (CD32) and Hb AS polymorphisms [<xref ref-type="bibr" rid="B17">17</xref>], as well as GM and KM allotypes of IgG, differ significantly between the Fulani and non-Fulani ethnic groups [<xref ref-type="bibr" rid="B14">14</xref>]. On the basis of these observations, it may be hypothesized that the Fc&#x003b3;RIIa genotype, GM and KM allotypes may contribute to the interethnic differences in malaria susceptibility, possibly in part by influencing the IgG subclass pattern of the anti-malarial antibodies.</p><p>In this study, the influence of the Fc&#x003b3;RIIa-R/H131 polymorphisms on the IgG subclass patterns of antibodies to four malaria vaccine candidate antigens was analysed in the Fulani and their sympatric non-Fulani ethnic groups in eastern Sudan.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study area</title><p>A detailed description of the study area has been previously reported [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. The study was carried out before the rainy seasons between 2004 and 2006 in the Daraweesh village, Gedaref State in eastern Sudan. Daraweesh is 450 km from Khartoum and 16 km from Gedaref town. It is inhabited by approximately 420 Arabic speakers of Fulani ethnic origin whose ancestors settled in this area about a century ago [<xref ref-type="bibr" rid="B20">20</xref>]. The village economy is based on agriculture. Malaria transmission is markedly seasonal and unstable and annual peak parasite prevalence ranges from 1 to 40% in different years. The transmission is hypo-endemic and the acquisition of clinical immunity with age is not as obvious as seen in holo-endemic areas and thus malaria remains a problem in all age groups [<xref ref-type="bibr" rid="B20">20</xref>]. <italic>Plasmodium falciparum </italic>is responsible for &#x0003e;96% malaria cases, the remainder being <italic>Plasmodium vivax </italic>and <italic>Plasmodium malariae</italic>. <italic>Anopheles arabiensis </italic>is the sole vector.</p></sec><sec><title>Study population</title><p>This study is a part of a longitudinal study of infection and immunity to malaria in Daraweesh, which has been going on since 1990. The study received approval from the ethical Committee of the University of Khartoum and national clearance from the Sudanese Ministry of Health. In this Daraweesh population, who are of Fulani origin, a study showed distinctly variable level of disease susceptibility [<xref ref-type="bibr" rid="B16">16</xref>]. In the present study, data and samples from a cohort of 250 permanent residents (162 female, 88 male; median of age in 2005, 15.5 years, with the range 4&#x02013;75 years), monitored clinically and parasitologically by passive case detection for up to 11 years were used. During the malaria transmission season, all individuals feeling unwell reported to the health team that was present in the village on daily basis. A total of 101 subjects from the sympatric non-Fulani ethnic neighbours &#x02013; Masaleit (51%), Hausa (27.7%) and Four (21.8%) [<xref ref-type="bibr" rid="B14">14</xref>], were consecutively selected for the study (60 female, 41 male; median of age in 2005, 17.0 years, with the range 2&#x02013;55 years). All blood samples were collected before the rainy season and all individuals were asymptomatic and negative for <italic>Plasmodium </italic>parasites.</p></sec><sec><title>Blood collection for genotype and ELISA analysis</title><p>Three ml of peripheral blood were collected from the individuals into vacuum EDTA tubes. The collected blood samples were centrifuged for 15 minutes at 250 g. The layer of white cells on top of red blood cells were collected into sterile cryotubes and stored frozen at -20&#x000b0;C for DNA extraction and Fc&#x003b3;RIIa genotyping. The plasma was transferred into cryotubes stored at -20&#x000b0;C until use for antibody detection.</p></sec><sec><title>DNA purification</title><p>Genomic DNA was purified from the buffy-coat cells using a modified version of the Chelex-100 method and then stored at -20&#x000b0;C [<xref ref-type="bibr" rid="B21">21</xref>]. In brief, 25 ml from the cells were incubated overnight at 4&#x000b0;C in 1 ml of 0.5% saponin in 1&#x000d7; phosphate-buffered saline (PBS). The pellet was washed for 30 min with PBS at 4&#x000b0;C, and the supernatant discarded. The pellet was boiled in 120 ml of 5% Chelex-100 in water for 15 min, and the DNA was collected in the supernatants after centrifugation at 250 g for 3 min.</p></sec><sec><title>Genotyping of the Fc&#x003b3;RIIa gene</title><p>The Fc&#x003b3;RIIa genotype was determined using a modified version of a polymerase chain reaction (PCR) method [<xref ref-type="bibr" rid="B22">22</xref>]. The PCR conditions were as follows: one cycle at 96&#x000b0;C for five minutes, 30 cycles at 94&#x000b0;C for 30 sec and 56&#x000b0;C for 30 sec, and one cycle at 72&#x000b0;C for 45 sec. The PCR product was digested for 2 h at 37&#x000b0;C using the restriction enzyme <italic>Bst</italic>UI (Fermentas Inc. MD, USA), according to the manufacturer's recommendation. The enzyme cuts at one site in the R131 allele and twice in the H131 allele. The fragments were resolved by electrophoresis in a 2% agarose gel.</p></sec><sec><title>Measurement of antibodies</title><p>The levels of serum antibodies (IgG total and subclasses) to four malaria antigens (AMA-1, MSP 2 &#x02013; 3D7 &#x00026; FC27, Pf332-C231) were measured using enzyme-linked immunosorbent assays (ELISA), mainly as previously described [<xref ref-type="bibr" rid="B23">23</xref>]. Briefly, EIA/RIA plates (Costar, MA, USA) were coated with AMA-1 at 1 &#x003bc;g/ml, 3D7-MSP 2 and FC27-MSP 2 at 1 &#x003bc;g/ml, and Pf332-C231 at 5 &#x003bc;g/ml. The AMA-1 protein, which has an N-terminal hexa-His tag, was expressed in <italic>Escherichia coli </italic>and refolded <italic>in vitro </italic>[<xref ref-type="bibr" rid="B24">24</xref>]. Both the 3D7 and FC27 forms of MSP 2 were expressed in <italic>E. coli </italic>with C-terminal hexa-His tags. The expression and purification of these proteins will be described elsewhere (Hobba <italic>et al</italic>, manuscript in preparation). The recombinant Pf332-C231 corresponds to a 231-amino acid fragment in the C-terminal part of Pf332 [<xref ref-type="bibr" rid="B25">25</xref>]. The plates were incubated overnight at 4&#x000b0;C, and then blocked for 2 hrs with 0.5% bovine serum albumin (BSA) diluted in carbonate buffer (pH 9.6). Plasma samples diluted in incubation buffer (PBS + 0.5% BSA), 1:1,000 (IgG) and 1:400 (IgG1&#x02013;4), were added in duplicate and incubated for 1 h at 37&#x000b0;C. The plates were than washed four times, and bound IgG antibodies were detected with goat anti-human IgG-ALP (1:2000) (Mabtech, Nacka, Sweden). IgG subclasses were analysed with their respective biotin conjugated mouse anti-human subclass specific monoclonal antibodies: mouse anti-human IgG1 1:1,000 (M15015, Clone NL16, SkyBio, Bedfordshire, UK), mouse anti-human IgG2 1:3,000 (555874, Pharmingen, Erembodegem, Belgium), mouse anti-human IgG3 1:1,000 (MH 1532, Caltag laboratories, Paisley, UK) and mouse anti-human IgG4 1:2,000 (B3648, Sigma, St. Louis, USA). Alkaline phosphatase (ALP) conjugated streptavidin (Mabtech) diluted 1:2,000 was added to detect bound antibodies of IgG2&#x02013;4, while ALP-conjugated to goat anti-mouse Ig (Dakopatts, Glostrup, Denmark; 1:1,000) were used for IgG1 antibodies and the plates were developed with nitrophenyl phosphate (Sigma-Aldrich Chemie GmbH, Steinheim, Germany). The absorbance was read at 405 nm using a Vmax&#x02122; Kinetic microplate reader (Molecular devices, Menlo Park, USA) and the antibody concentrations were deduced from the log-log correlative coefficient of each IgG subclass standard curve (six dilutions of myeloma proteins of IgG1&#x02013;4 subclasses), ranging from 0.01 to 3 &#x003bc;g/ml for IgG1, 0.001 to 0.3 &#x003bc;g/ml for IgG2, 0.001 to 0.1 &#x003bc;g/ml for IgG3 and 0.01 to 1 &#x003bc;g/ml for IgG4 according to the manufacturer's recommendation (Biogenesis, Poole, England).</p></sec><sec><title>Statistical analysis</title><p>Fc&#x003b3;RIIa genotype, allele frequencies and antibody levels were analysed using SPSS version 10.0 (SPSS, Inc, Chicago, IL, USA). Logistic regression analysis was performed with age, sex and antibodies modelled as binary dummy variables (ranked into third distribution using the first third as the reference indicator). Associations were quantified using odds ratios [OR] with 95% confidence intervals [CI] that did not cross 1.00 with P value &#x0003c; 0.05, defined as statistically significant. The Fc&#x003b3;RIIa-His/Arg131 group was used as a reference in the analyses, because this genotype is the most prevalent in human populations [<xref ref-type="bibr" rid="B26">26</xref>]. An overall comparison of allele frequency using a 2 &#x000d7; 2 chi-square test was performed using the same software.</p></sec></sec><sec><title>Results</title><p>A total of 351 individuals were included in the study, 202 (63.2%) females and 129 (36.8) males, with an overall age range of 2 to 75 years. No donor had any malaria parasites detectable by microscopy at the time of sampling; this result was confirmed by PCR screening of the samples (not listed).</p><sec><title>Fc&#x003b3;RIIa-R/H131 genotype and allele frequencies in the sympatric ethnic groups</title><p>All individuals of the two study groups were genotyped for the Fc&#x003b3;RIIa-H/R131 SNP. The H/H131 genotype was at higher frequency in the Fulani than in the non-Fulani ethnic group (36.0% for Fulani versus 17.8% for non-Fulani; unadjusted OR 2.67, 95% CI 1.48&#x02013;4.83, P &#x0003c; 0.001 and adjusted OR 3.10, 95% CI 1.61&#x02013;5.97, P &#x0003c; 0.001) (Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>). In contrast, there were no differences between the two groups in the frequency of R/R 131 genotype (17.6% for Fulani versus 20.8% non-Fulani; adjusted OR 0.99, 95% CI 0.52&#x02013;1.89, P value 0.98) (Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>). However, when using the H/H131 genotype as a reference group in the statistical analysis, the heterozygote H/R131 genotype was found to be statistically significantly at higher frequency in the non-Fulani than in Fulani (46.4% for Fulani versus 61.4% for non-Fulani; adjusted OR 0.34, 95% CI 0.18&#x02013;0.62, P &#x0003c; 0.001) (Table <xref ref-type="table" rid="T2">2</xref>). A similar significant difference was seen for the R/R131 genotype, also being at higher frequency in non-Fulani as compared with Fulani (17.6% for Fulani versus 20.8% for non-Fulani; adjusted OR 0.36, 95% CI 0.17&#x02013;0.77, P &#x0003c; 0.001) (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Distribution of the Fc&#x003b3;RIIa-131 genotypes and allele frequency in the sympatric ethnic groups</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left" colspan="3"><bold>Fc&#x003b3;RIIa genotypes</bold></td></tr><tr><td align="left"><bold>Ethnic</bold></td><td align="left"><bold>H/H131</bold></td><td align="left"><bold>H/R131</bold></td><td align="left"><bold>R/R131</bold></td></tr></thead><tbody><tr><td align="left">Fulani n (%)</td><td align="left">90 (36.0%)</td><td align="left">116 (46.4%)</td><td align="left">44 (17.6%)</td></tr><tr><td align="left">Non-Fulani n (%)</td><td align="left">18 (17.8%)</td><td align="left">62 (61.4%)</td><td align="left">21 (20.8%)</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>Allele Frequency*</bold></td><td align="left"><bold>H131</bold></td><td align="left"><bold>R131</bold></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Fulani</td><td align="left">0.60</td><td align="left">0.40</td><td></td></tr><tr><td align="left">Non-Fulani</td><td align="left">0.49</td><td align="left">0.51</td><td></td></tr></tbody></table><table-wrap-foot><p>* 0.60 for Fulani versus 0.40 non-Fulani; OR 1.54, 95% CI (1.09&#x02013;2.17), P value 0.01</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Logistic regression analysis of Fc&#x003b3;RIIa genotypes in Fulani compared with non-Fulani ethnic groups</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold><italic>Unadjusted </italic>Odds ratio (95% CI)</bold></td><td align="center"><bold><italic>p </italic>value</bold></td><td align="center"><bold><italic>Adjusted* </italic>Odds ratio (95% Cl)</bold></td><td align="center"><bold><italic>p </italic>value</bold></td></tr></thead><tbody><tr><td align="center">H/H131</td><td align="center">2.67 (1.48&#x02013;4.83)</td><td align="center">&#x0003c; 0.001</td><td align="center">3.10 (1.61&#x02013;5.97)</td><td align="center">&#x0003c; 0.001</td></tr><tr><td align="center">R/H131</td><td align="center">1.00</td><td></td><td align="center">1.00</td><td></td></tr><tr><td align="center">R/R131</td><td align="center">1.12 (0.61&#x02013;2.05)</td><td align="center">0.71</td><td align="center">0.99 (0.52&#x02013;1.89)</td><td align="center">0.98</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="center">H/H131</td><td align="center">1.00</td><td></td><td align="center">1.00</td><td></td></tr><tr><td align="center">R/H131</td><td align="center">0.37 (0.21&#x02013;0.68)</td><td align="center">&#x0003c; 0.001</td><td align="center">0.34 (0.18&#x02013;0.62)</td><td align="center">&#x0003c; 0.001</td></tr><tr><td align="center">R/R131</td><td align="center">0.42 (0.20&#x02013;0.87)</td><td align="center">0.02</td><td align="center">0.36 (0.17&#x02013;0.77)</td><td align="center">0.01</td></tr></tbody></table><table-wrap-foot><p>*Adjustment of Odds ratio was performed for sex, age</p></table-wrap-foot></table-wrap><p>A genetic difference between the two ethnic groups was also evident when comparing the Fc&#x003b3;RIIa-R/H131 allele frequencies, the H131 allele being more common in the Fulani (0.60 for Fulani versus 0.49 non-Fulani; OR 1.54, 95% CI 1.09&#x02013;2.17, P value 0.01) (Table <xref ref-type="table" rid="T1">1</xref>). No such interethnic difference was seen for the R131 allele. The overall genotypic frequencies did not differ statistically among the different age groups within the ethnic groups, neither in the Fulani (P value 0.26) nor in the non-Fulani (P value 0.59). No gender dependent differences in genotype frequencies were seen (P = 0.61).</p></sec><sec><title>IgG antibody reactivities</title><p>In this study, antibody responses to four <italic>P. falciparum </italic>blood-stage antigens, AMA-1, MSP2 &#x02013; 3D7, &#x02013; FC27 and Pf332-C231, were analysed in the Fulani and the non-Fulani ethnic groups. There were no statistically significant differences in anti-malarial total IgG antibody levels between the ethnic groups, and therefore the following analyses were limited only to the IgG subclasses. In general, IgG1 and IgG3 subclass antibodies were found to be at higher levels than IgG2 and IgG4 antibodies in both ethnic groups. However, the antibody levels varied for the different antigens. When comparing the antibody levels between the two ethnic groups, the non-Fulani showed significantly higher levels of IgG1 antibodies reactive with AMA-1 (P &#x0003c; 0.001), and also tended to have higher IgG3 antibody levels (P = 0.062) (Table <xref ref-type="table" rid="T3">3</xref>). The IgG2 antibody responses reactive with AMA-1 were, however, statistically significantly higher in the Fulani than in the non-Fulani ethnic group (P = 0.024) (Table <xref ref-type="table" rid="T3">3</xref>). While antibodies reactive with MSP2-3D7 showed a similar pattern of interethnic differences in IgG subclass levels as those reactive with AMA-1, IgG1 antibodies reactive with MSP2-FC27 were at higher levels in the Fulani as compared to the non-Fulani (P = 0.041) (Table <xref ref-type="table" rid="T3">3</xref>). Regarding Pf332-C231 reactive antibodies, IgG3 and IgG4 subclasses were significantly higher in the non-Fulani than in the Fulani (P &#x0003c; 0.001) (Table <xref ref-type="table" rid="T3">3</xref>). No differences in levels of antibodies of the different IgG subclasses were seen among the different ethnicities within the non-Fulani group.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Logistic regression analysis of immunoglobulin classes in Fulani and Non-Fulani ethnic groups</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Antigen</bold></td><td align="left"><bold>IgG subclass</bold></td><td align="left"><bold>OR<sup>&#x02020; </sup>(95% CI)</bold></td><td align="left"><bold><italic>p </italic>value</bold></td></tr></thead><tbody><tr><td align="left">AMA-1</td><td align="left">IgG1</td><td align="left">1.2 (1.1 to 1.3)</td><td align="left">&#x0003c; 0.001</td></tr><tr><td></td><td align="left">IgG2</td><td align="left">0.6 (0.3 to 0.9)</td><td align="left">0.024</td></tr><tr><td></td><td align="left">IgG3</td><td align="left">2.2 (0.9 to 5.4)</td><td align="left">0.062</td></tr><tr><td></td><td align="left">IgG4</td><td align="left">0.4 (0.1 to 1.2)</td><td align="left">0.113</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left">3D7-MSP2</td><td align="left">IgG1</td><td align="left">1.1 (1.0 to 1.2)</td><td align="left">0.015</td></tr><tr><td></td><td align="left">IgG2</td><td align="left">0.6 (0.4 to 0.9)</td><td align="left">0.018</td></tr><tr><td></td><td align="left">IgG3</td><td align="left">1.0 (1.0 to 1.0)</td><td align="left">0.069</td></tr><tr><td></td><td align="left">IgG4</td><td align="left">0.1 (0.05 to 0.3)</td><td align="left">&#x0003c; 0.001</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left">FC27-MSP2</td><td align="left">IgG1</td><td align="left">0.5 (0.2 to 0.9)</td><td align="left">0.041</td></tr><tr><td></td><td align="left">IgG2</td><td align="left">2.9 (1.2 to 7.1)</td><td align="left">0.016</td></tr><tr><td></td><td align="left">IgG3</td><td align="left">2.2 (1.4 to 3.3)</td><td align="left">&#x0003c; 0.001</td></tr><tr><td></td><td align="left">IgG4</td><td align="left">0.5 (0.2 to 1.3)</td><td align="left">0.159</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td align="left">Pf332-C231</td><td align="left">IgG1</td><td align="left">2.5 (0.8 to 6.8)</td><td align="left">0.081</td></tr><tr><td></td><td align="left">IgG2</td><td align="left">1.0 (0.9 to 1.0)</td><td align="left">0.978</td></tr><tr><td></td><td align="left">IgG3</td><td align="left">2.7 (1.6 to 4.3)</td><td align="left">&#x0003c; 0.001</td></tr><tr><td></td><td align="left">IgG4</td><td align="left">8.1 (3.5 to 18.6)</td><td align="left">&#x0003c; 0.001</td></tr></tbody></table><table-wrap-foot><p><sup>&#x02020; </sup>OR represent odds ratios while CI represents confidence intervals. Fulani were assigned 0 while non-Fulani were assigned 1 in the logistic regression analysis. OR above 1 represented value associated to non-Fulani while less than 1 value represented Fulani.</p></table-wrap-foot></table-wrap></sec><sec><title>Fc&#x003b3;RIIa genotype and <italic>P. falciparum</italic>-specific IgG subclass distribution</title><p>In order to see if the Fc&#x003b3;RIIa genotype affected the specific IgG subclass levels, using four different malarial antigens, the relationship between Fc&#x003b3;RIIa genotype and IgG antibody subclasses was analysed. For the study population as a whole, including both the Fulani and the non-Fulani individuals, the H/H131 genotype was statistically significantly associated with higher levels of IgG2 (P &#x0003c; 0.001), IgG3 (P = 0.01) and IgG4 antibodies against AMA-1 (P = 0.01) (Table <xref ref-type="table" rid="T4">4</xref>). Furthermore, there was a trend for an association of the R/R131 genotype with higher levels of IgG1 antibodies against AMA-1 (P = 0.05) (Table <xref ref-type="table" rid="T4">4</xref>). Interethnic comparison of AMA-1 reactive antibodies in relation to Fc&#x003b3;RIIa genotypes showed that non-Fulani H/H 131 carriers had significantly higher levels of IgG1 (adjusted OR 0.04, 95% CI 0.02&#x02013;0.12; P &#x0003c; 0.001) and IgG3 (adjusted OR 0.31, 95% CI 0.17&#x02013;0.57; P &#x0003c; 0.001) (Table <xref ref-type="table" rid="T5">5</xref>). No such interethnic differences were found for the IgG2 and IgG4 antibody subclasses.</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Logistic regression analysis of Fc&#x003b3;RIIa-H/R131 genotypes in relation to anti-malarial IgG subclasses in the combined study populations</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Anti-malarial antibodies</bold></td><td align="center"><bold>Fc&#x003b3;RIIa-H/R131 genotypes</bold></td><td align="center"><bold>OR<sup>&#x02020; </sup>(95% CI)</bold></td><td align="center"><bold><italic>p </italic>value</bold></td></tr></thead><tbody><tr><td align="center"><bold><underline>AMA-1</underline></bold></td><td></td><td></td><td></td></tr><tr><td align="center">IgG1</td><td align="center">H/H</td><td align="center">1.15 (0.57&#x02013;2.31)</td><td align="center">0.70</td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">1.91 (1.00&#x02013;3.64)</td><td align="center"><bold>0.05</bold></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG2</td><td align="center">H/H</td><td align="center">2.65 (1.43&#x02013;4.91)</td><td align="center"><bold>&#x0003c; 0.001</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">1.34 (0.69&#x02013;2.61)</td><td align="center">0.38</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG3</td><td align="center">H/H</td><td align="center">2.26 (1.21&#x02013;4.22)</td><td align="center"><bold>0.01</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">1.38 (0.70&#x02013;2.72)</td><td align="center">0.35</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG4</td><td align="center">H/H</td><td align="center">2.93 (1.33&#x02013;6.41)</td><td align="center"><bold>0.01</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">1.15 (0.53&#x02013;2.48)</td><td align="center">0.72</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center"><bold><underline>3D7-MSP2</underline></bold></td><td></td><td></td><td></td></tr><tr><td align="center">IgG1</td><td align="center">H/H</td><td align="center">0.10 (0.03&#x02013;0.20)</td><td align="center"><bold>&#x0003c; 0.001</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.86 (0.41&#x02013;1.80)</td><td align="center">0.69</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG2</td><td align="center">H/H</td><td align="center">2.76 (1.32&#x02013;4.47)</td><td align="center"><bold>&#x0003c; 0.001</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">1.27 (0.66&#x02013;2.46)</td><td align="center">0.48</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG3</td><td align="center">H/H</td><td align="center">2.37 (1.28&#x02013;4.38)</td><td align="center"><bold>0.01</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">1.21 (0.62&#x02013;2.35)</td><td align="center">0.58</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG4</td><td align="center">H/H</td><td align="center">2.40 (1.29&#x02013;4.45)</td><td align="center"><bold>0.01</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">1.47 (0.74&#x02013;2.92)</td><td align="center">0.27</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center"><bold><underline>FC27-MSP2</underline></bold></td><td></td><td></td><td></td></tr><tr><td align="center">IgG1</td><td align="center">H/H</td><td align="center">1.26 (0.65&#x02013;2.43)</td><td align="center">0.50</td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">2.38 (1.29&#x02013;4.39)</td><td align="center"><bold>0.01</bold></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG2</td><td align="center">H/H</td><td align="center">2.37 (1.28&#x02013;4.38)</td><td align="center"><bold>0.01</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">1.21 (0.62&#x02013;2.35)</td><td align="center">0.58</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG3</td><td align="center">H/H</td><td align="center">2.86 (1.50&#x02013;5.46)</td><td align="center"><bold>&#x0003c; 0.001</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">1.45 (0.70&#x02013;3.02)</td><td align="center">0.32</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG4</td><td align="center">H/H</td><td align="center">2.46 (1.33&#x02013;4.55)</td><td align="center"><bold>&#x0003c; 0.001</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">1.77 (0.66&#x02013;2.48)</td><td align="center">0.47</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center"><bold><underline>Pf332-C231</underline></bold></td><td></td><td></td><td></td></tr><tr><td align="center">IgG1</td><td align="center">H/H</td><td align="center">1.33 (0.68&#x02013;2.59)</td><td align="center">0.40</td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">2.43 (1.31&#x02013;4.50)</td><td align="center"><bold>0.01</bold></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG2</td><td align="center">H/H</td><td align="center">2.26 (1.21&#x02013;4.22)</td><td align="center"><bold>0.01</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">1.38 (0.70&#x02013;2.72)</td><td align="center">0.35</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG3</td><td align="center">H/H</td><td align="center">2.44 (1.32&#x02013;4.51)</td><td align="center"><bold>&#x0003c; 0.001</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">1.18 (0.61&#x02013;2.30)</td><td align="center">0.62</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG4</td><td align="center">H/H</td><td align="center">1.79 (0.92&#x02013;3.49)</td><td align="center">0.10</td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">1.33 (0.59&#x02013;2.97)</td><td align="center">0.50</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Logistic regression analysis of Fc&#x003b3;RIIa-H/R131 genotypes in relation to anti-malarial IgG subclasses in Fulani compared with non-Fulani groups</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Anti-malarial antibodies</bold></td><td align="center"><bold>Fc&#x003b3;RIIa-H/R131 genotypes</bold></td><td align="center"><bold>OR<sup>&#x02020; </sup>(95% CI)</bold></td><td align="center"><bold><italic>p </italic>value</bold></td></tr></thead><tbody><tr><td align="center"><bold><underline>AMA-1</underline></bold></td><td></td><td></td><td></td></tr><tr><td align="center">IgG1</td><td align="center">H/H</td><td align="center">0.04 (0.02&#x02013;0.12)</td><td align="center"><bold>&#x0003c; 0.001</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.86 (0.42&#x02013;1.78)</td><td align="center">0.69</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG2</td><td align="center">H/H</td><td align="center">0.70 (0.35&#x02013;1.37)</td><td align="center">0.30</td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.61 (0.34&#x02013;1.11)</td><td align="center">0.10</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG3</td><td align="center">H/H</td><td align="center">0.31 (0.17&#x02013;0.57)</td><td align="center"><bold>&#x0003c; 0.001</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.69 (0.34&#x02013;1.38)</td><td align="center">0.30</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG4</td><td align="center">H/H</td><td align="center">0.59 (0.30&#x02013;1.15)</td><td align="center">0.12</td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.90 (0.41&#x02013;1.95)</td><td align="center">0.78</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center"><bold><underline>3D7-MSP2</underline></bold></td><td></td><td></td><td></td></tr><tr><td align="center">IgG1</td><td align="center">H/H</td><td align="center">0.10 (0.03&#x02013;0.20)</td><td align="center"><bold>&#x0003c; 0.001</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.86 (0.41&#x02013;1.80)</td><td align="center">0.69</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG2</td><td align="center">H/H</td><td align="center">2.43 (1.32&#x02013;4.47)</td><td align="center"><bold>&#x0003c; 0.001</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.83 (0.41&#x02013;1.69)</td><td align="center">0.61</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG3</td><td align="center">H/H</td><td align="center">0.49 (0.26&#x02013;0.91)</td><td align="center"><bold>0.03</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.81 (0.40&#x02013;1.63)</td><td align="center">0.55</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG4</td><td align="center">H/H</td><td align="center">2.76 (1.45&#x02013;5.26)</td><td align="center"><bold>&#x0003c; 0.001</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.59 (0.28&#x02013;1.25)</td><td align="center">0.17</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center"><bold><underline>FC27-MSP2</underline></bold></td><td></td><td></td><td></td></tr><tr><td align="center">IgG1</td><td align="center">H/H</td><td align="center">0.53 (0.28&#x02013;1.01)</td><td align="center">0.10</td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.86 (0.42&#x02013;1.78)</td><td align="center">0.68</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG2</td><td align="center">H/H</td><td align="center">0.45 (0.24&#x02013;0.85)</td><td align="center"><bold>0.01</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.70 (0.35&#x02013;1.37)</td><td align="center">0.30</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG3</td><td align="center">H/H</td><td align="center">0.13 (0.10&#x02013;0.26)</td><td align="center"><bold>0.01</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.76 (0.37&#x02013;1.57)</td><td align="center">0.46</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG4</td><td align="center">H/H</td><td align="center">0.70 (0.36&#x02013;1.39)</td><td align="center">0.31</td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.97 (0.54&#x02013;1.74)</td><td align="center">0.92</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center"><bold><underline>Pf332-C231</underline></bold></td><td></td><td></td><td></td></tr><tr><td align="center">IgG1</td><td align="center">H/H</td><td align="center">1.25 (0.67&#x02013;2.30)</td><td align="center">0.48</td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.72 (0.36&#x02013;1.44)</td><td align="center">0.36</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG2</td><td align="center">H/H</td><td align="center">0.22 (0.11&#x02013;0.44)</td><td align="center"><bold>&#x0003c; 0.001</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.69 (0.34&#x02013;1.38)</td><td align="center">0.29</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG3</td><td align="center">H/H</td><td align="center">4.25 (2.28&#x02013;7.91)</td><td align="center"><bold>&#x0003c; 0.001</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.91 (0.45&#x02013;1.84)</td><td align="center">0.80</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">IgG4</td><td align="center">H/H</td><td align="center">0.10 (0.03&#x02013;0.20)</td><td align="center"><bold>&#x0003c; 0.001</bold></td></tr><tr><td></td><td align="center">H/R</td><td align="center">1</td><td></td></tr><tr><td></td><td align="center">R/R</td><td align="center">0.69 (0.26&#x02013;1.42)</td><td align="center">0.25</td></tr></tbody></table></table-wrap><p>Regarding antibodies reactive with MSP2-3D7 or -FC27 in the study population as a whole, a similar pattern as with AMA-1 reactive antibodies was seen. The H/H 131 genotype carriers showed statistically significantly higher levels of IgG2 (P &#x0003c; 0.001 and = 0.01, respectively), IgG3 (P = 0.01 for both antigens) and IgG4 (P = 0.01 and &#x0003c; 0.001, respectively), while the R/R 131 genotype carriers showed higher levels of IgG1 antibodies (P = 0.01 for both antigens) (Table <xref ref-type="table" rid="T4">4</xref>).</p><p>Interethnic comparison of MSP2-3D7 reactive antibodies in relation to Fc&#x003b3;RIIa genotypes showed that non-Fulani H/H 131 carriers had significantly higher levels of IgG1 (adjusted OR 0.10, 95% CI 0.03&#x02013;0.20; P &#x0003c; 0.001) and IgG3 (adjusted OR 0.49, 95% CI 0.26&#x02013;0.91; P value 0.03), while Fulani H/H 131 carriers showed higher levels of IgG2 (adjusted OR 2.43, 95% CI 1.32&#x02013;4.47; P &#x0003c; 0.001) and IgG4 antibodies (adjusted OR 2.76, 95% CI 1.45&#x02013;5.26; P &#x0003c; 0.001) (Table <xref ref-type="table" rid="T5">5</xref>). In contrast, an interethnic comparison for MSP2-FC27 reactive antibodies, showed that the non-Fulani H/H 131 genotype carriers had significantly higher levels of IgG2 (adjusted OR 0.45, 95% CI 0.24&#x02013;0.85; P = 0.01) and IgG3 (adjusted OR 0.13, 95% CI 0.10&#x02013;0.26; P &#x0003c; 0.001) than the Fulani, while no significant interethnic differences were found regarding IgG1 and IgG4 antibody levels with any of the genotypes (Table <xref ref-type="table" rid="T5">5</xref>).</p><p>Regarding antibodies reactive with Pf332-C231 in the study population as a whole, the H/H131 genotype was statistically significantly associated with higher levels of IgG2 (P = 0.01) and IgG3 (P &#x0003c; 0.001) (Table <xref ref-type="table" rid="T4">4</xref>). Furthermore, the R/R131 genotype was statistically significantly associated with higher levels of IgG1 antibodies reactive with this antigen (P = 0.01) (Table <xref ref-type="table" rid="T4">4</xref>).</p><p>Interethnic comparison of Pf332-C231 reactive antibodies in relation to Fc&#x003b3;RIIa genotypes showed that non-Fulani H/H 131 carriers had significantly higher levels of IgG2 (adjusted OR 0.22, 95% CI 0.11&#x02013;0.44; P &#x0003c; 0.001) and IgG4 (adjusted OR 0.10, 95% CI 0.03&#x02013;0.20; P &#x0003c; 0.001), IgG3 antibodies were at significantly higher levels in H/H 131 carriers of the Fulani group (adjusted OR 4.25, 95% CI 2.28&#x02013;7.91; P &#x0003c; 0.001) (Table <xref ref-type="table" rid="T5">5</xref>).</p></sec></sec><sec><title>Discussion</title><p>The present study confirms and extends the previous finding in the same study population, that the prevalence of the Fc&#x003b3;RIIa-H/H131 genotype and the H131 allele are statistically significantly higher in Fulani than in sympatric non-Fulani children [<xref ref-type="bibr" rid="B17">17</xref>]. The prevalence of both the Fc&#x003b3;RIIa-H/H131 genotype and the H131 allele was similar in the different age groups of the Fulani, indicating that the H131 allele carriage has no evident influence on the survival of the individuals. Interestingly, a similar higher frequency of the H/H131 genotype and H131 allele was recently observed also in the Fulani living in Mali, compared to the sympatric ethnic group, the Dogon [<xref ref-type="bibr" rid="B27">27</xref>]. It is well established that the Fulani in Mali and Burkina Faso are less affected by malaria than other sympatric ethnic groups, the Dogon and the Mossi/Rimaib&#x000e9;, respectively [<xref ref-type="bibr" rid="B12">12</xref>]. Similarly, the Fulani in the present study site has been shown to have lower <italic>P. falciparum </italic>parasite densities and parasite rates than the neighbouring ethnic group, the Masaleit [<xref ref-type="bibr" rid="B17">17</xref>]. Whether the Fc&#x003b3;RIIa-R/H131 polymorphism is a contributing factor in the observed ethnic differences in susceptibility to malaria remains to be studied in different epidemiological settings.</p><p>Contrasting results have been reported regarding associations of Fc&#x003b3;RIIa-R/H131 genotypes with malaria disease outcomes [<xref ref-type="bibr" rid="B6">6</xref>]. Thus, one study observed an association between the H/H131 genotype and susceptibility to severe malaria [<xref ref-type="bibr" rid="B28">28</xref>], while others found R/R131 genotype carriers to be less likely to be at risk for high density <italic>P. falciparum </italic>infection, compared to the R/H131 heterozygotes [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. Another previous report has associated the H/H131 genotype with protection against malaria [<xref ref-type="bibr" rid="B1">1</xref>]. However, contrasting results also with regard to the R/R131 genotype and protection from malaria have been reported [<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B31">31</xref>]. The Fc&#x003b3;RIIa-R/R131 genotype in Sudanese patients was recently shown to be associated with higher risk to develop severe malaria [<xref ref-type="bibr" rid="B32">32</xref>], while in an Indian population, the H/H131 genotype was significantly associated with protection from malaria disease manifestation [<xref ref-type="bibr" rid="B33">33</xref>]. The discrepant results in this context may most likely be explained by genetic differences between the populations studied, as well as differences in gene-environment interactions and in patterns of malaria transmission in the different study areas.</p><p>Several studies in Burkina Faso and Mali have shown that the Fulani have significantly higher levels of anti-malarial antibodies than other sympatric ethnic groups [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B13">13</xref>], including antibodies of all the IgG subclasses, except IgG4 [<xref ref-type="bibr" rid="B8">8</xref>]. In contrast, in the present study, the non-Fulani had significantly higher levels of anti-malarial IgG1 and IgG3 antibodies than the Fulani for three of the four antigens studied, but not for MSP2-FC27. The Fulani, tended to have significantly higher levels of anti-malarial IgG2 antibodies than the non-Fulani group. These discrepant results seen in Burkina Faso, Mali and Sudan may most likely be explained by differences in patterns of malaria transmission in the different study areas [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. It should be recalled that Sudan is a country characterized by hypo/meso-endemicity, with seasonal and unstable malaria transmission, unlike Burkina Faso and Mali, characterized with hyper/holo-endemic malaria transmission [<xref ref-type="bibr" rid="B8">8</xref>]. In Daraweesh an entomological inoculation rate (EIR) of one infective bite/year has been estimated based on surveys in drought-free years [<xref ref-type="bibr" rid="B34">34</xref>]. Almost all malaria cases in Daraweesh are clinically uncomplicated, probably because of continuous monitoring by the health team that visits the village on a daily basis and provides free drug treatment [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B19">19</xref>].</p><p>While the Fc&#x003b3;RIIa-R131 molecule shows a similar binding of the cytophilic subclasses IgG1 and IgG3 [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>], the H131 receptor binds IgG3 more efficiently and is the only Fc&#x003b3;R that binds IgG2 efficiently [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B37">37</xref>-<xref ref-type="bibr" rid="B40">40</xref>]. Thus, in the presence of the Fc&#x003b3;RIIa-H131 receptor, IgG2 antibodies should also be considered as cytophilic, and thus this receptor is essential for effective IgG2-mediated cellular activation. The present study indicates that the differential recognition of the IgG subclasses by the R131 and H131 Fc&#x003b3;RIIa may have an impact on the pattern of IgG subclasses in the anti-malarial immune response. Higher levels of IgG2 and IgG3 antibodies were associated with the H/H genotype, while higher levels of IgG1 antibodies were associated with the R/R131 genotype. In line with this, the Fulani showed a higher frequency of the Fc&#x003b3;RIIa-H131 allele and higher levels of anti-malarial IgG2 antibodies than sympatric non-Fulani ethnic groups. A similar higher frequency of the Fc&#x003b3;RIIa-H131 allele and a higher proportion of IgG2 among the anti-malarial antibodies, were recently observed in the Fulani in Mali compared to a sympatric non-Fulani ethnic group [<xref ref-type="bibr" rid="B27">27</xref>].</p><p>There is accumulating evidence for IgG1 and IgG3 antibodies playing an important role in protection against malarial disease [<xref ref-type="bibr" rid="B41">41</xref>]. However, the contribution of parasite-reactive IgG2 antibodies in protection against clinical malaria [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B42">42</xref>] and/or in susceptibility to disease [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B43">43</xref>] has been indicated in some epidemiological settings. In Burkina Faso, the association between anti-malarial IgG2 antibodies and protection against malaria, was suggested to be due to the relatively high prevalence of the IgG2 binding H/H131 genotype in that study population [<xref ref-type="bibr" rid="B42">42</xref>]. Whether the higher levels of anti-malarial IgG2 antibodies and the higher frequency of the Fc&#x003b3;RIIa-H131 allele in the Fulani contributes to the lower susceptibility to malaria in this ethnic group as compared to sympatric non-Fulani ethnic groups, remains to be investigated in extended epidemiological studies.</p></sec><sec><title>Conclusion</title><p>The present study confirms and extends the previous findings that the Fc&#x003b3;RIIa-H/H131 genotype and the H131 allele are more frequent in the Fulani, than in their sympatric ethnic neighbours. The Fulani in Sudan had lower anti-malarial IgG1 and IgG3 antibody levels than the non-Fulani and higher levels of IgG2 antibodies. The higher IgG2 antibody levels seen in the Fulani may be due to the relatively high prevalence for the H/H131 genotype in this group. Further studies are needed to elucidate if the Fc&#x003b3;RIIa-R/H131 polymorphism may be a contributing factor to the differential susceptibility to malaria seen in different ethnic groups.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interest.</p></sec><sec><title>Authors' contributions</title><p>AN carried out the sampling, the genotyping of Fc&#x003b3;RIIa polymorphism and participated in the statistical analysis. NCI performed the ELISA and also participated in the statistical analysis. Both AN and NCI drafted the manuscript. GE, KB, HG and MT designed the study and set up the framework, financed and revised the manuscript. HAB and RFA prepared and provided the antigens used in the study and participated in the manuscript preparation. All authors read and approved the final version of the manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We are grateful to the villagers of Daraweesh and El-Kajara for their sustained cooperation and generous hospitality during over a decade of field work. We would like to thank the field assistants Mr. Mustafa Hamid Ali and Mrs Ihsan E. Osman at Gedaref malaria research station for their support. We are also grateful to the co-operation of the Malaria Research Centre (Mala.R.C), Department of Biochemistry, Faculty of Medicine, University of Khartoum, Sudan. We also thank Dr. Salah Farouk for assistance in the statistical analysis. This work was supported by grants from the Swedish Agency for Research Development with Developing Countries (SIDA, SAREC), the Swedish Medical Research Council (VR), as well as a grant within the BioMalPar European Network of Excellence (LSHP-CT-2004-503578).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ouma</surname><given-names>C</given-names></name><name><surname>Keller</surname><given-names>CC</given-names></name><name><surname>Opondo</surname><given-names>DA</given-names></name><name><surname>Were</surname><given-names>T</given-names></name><name><surname>Otieno</surname><given-names>RO</given-names></name><name><surname>Otieno</surname><given-names>MF</given-names></name><name><surname>Orago</surname><given-names>AS</given-names></name><name><surname>Ong'Echa</surname><given-names>JM</given-names></name><name><surname>Vulule</surname><given-names>JM</given-names></name><name><surname>Ferrell</surname><given-names>RE</given-names></name><name><surname>Perkins</surname><given-names>DJ</given-names></name></person-group><article-title>Association of FC gamma receptor IIA (CD32) polymorphism with malarial anemia and high-density parasitemia in infants and young children</article-title><source>Am J Trop Med Hyg</source><year>2006</year><volume>74</volume><fpage>573</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">16606986</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cavanagh</surname><given-names>DR</given-names></name><name><surname>McBride</surname><given-names>JS</given-names></name></person-group><article-title>Antigenicity of recombinant proteins derived from <italic>Plasmodium falciparum </italic>merozoite surface protein 1</article-title><source>Mol Biochem Parasitol</source><year>1997</year><volume>85</volume><fpage>197</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">9106193</pub-id><pub-id pub-id-type="doi">10.1016/S0166-6851(96)02826-5</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elhassan</surname><given-names>IM</given-names></name><name><surname>Hviid</surname><given-names>L</given-names></name><name><surname>Jakobsen</surname><given-names>PH</given-names></name><name><surname>Giha</surname><given-names>H</given-names></name><name><surname>Satti</surname><given-names>GM</given-names></name><name><surname>Arnot</surname><given-names>DE</given-names></name><name><surname>Jensen</surname><given-names>JB</given-names></name><name><surname>Theander</surname><given-names>TG</given-names></name></person-group><article-title>High proportion of subclinical <italic>Plasmodium falciparum </italic>infections in an area of seasonal and unstable malaria in Sudan</article-title><source>Am J Trop Med Hyg</source><year>1995</year><volume>53</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">7625539</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giha</surname><given-names>HA</given-names></name><name><surname>Theander</surname><given-names>TG</given-names></name><name><surname>Staalso</surname><given-names>T</given-names></name><name><surname>Roper</surname><given-names>C</given-names></name><name><surname>Elhassan</surname><given-names>IM</given-names></name><name><surname>Babiker</surname><given-names>H</given-names></name><name><surname>Satti</surname><given-names>GM</given-names></name><name><surname>Arnot</surname><given-names>DE</given-names></name><name><surname>Hviid</surname><given-names>L</given-names></name></person-group><article-title>Seasonal variation in agglutination of <italic>Plasmodium falciparum</italic>-infected erythrocytes</article-title><source>Am J Trop Med Hyg</source><year>1998</year><volume>58</volume><fpage>399</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">9574782</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabchareon</surname><given-names>A</given-names></name><name><surname>Burnouf</surname><given-names>T</given-names></name><name><surname>Ouattara</surname><given-names>D</given-names></name><name><surname>Attanath</surname><given-names>P</given-names></name><name><surname>Bouharoun-Tayoun</surname><given-names>H</given-names></name><name><surname>Chantavanich</surname><given-names>P</given-names></name><name><surname>Foucault</surname><given-names>C</given-names></name><name><surname>Chongsuphajaisiddhi</surname><given-names>T</given-names></name><name><surname>Druilhe</surname><given-names>P</given-names></name></person-group><article-title>Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria</article-title><source>Am J Trop Med Hyg</source><year>1991</year><volume>45</volume><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">1928564</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braga</surname><given-names>&#x000c9;M</given-names></name><name><surname>Gorza Scopel</surname><given-names>KG</given-names></name><name><surname>Komatsu</surname><given-names>NT</given-names></name><name><surname>Silva</surname><given-names>NM</given-names></name><name><surname>Ferreira</surname><given-names>MU</given-names></name></person-group><article-title>Polymorphism of the Fc&#x003b3; receptor IIA and malaria morbidity</article-title><source>J Mol Gen Med</source><year>2005</year><volume>1</volume><fpage>5</fpage><lpage>10</lpage></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warmerdam</surname><given-names>PA</given-names></name><name><surname>Winkel</surname><given-names>JG van de</given-names></name><name><surname>Vlug</surname><given-names>A</given-names></name><name><surname>Westerdaal</surname><given-names>NA</given-names></name><name><surname>Capel</surname><given-names>PJ</given-names></name></person-group><article-title>A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding</article-title><source>J Immunol</source><year>1991</year><volume>147</volume><fpage>1338</fpage><lpage>1343</lpage><pub-id pub-id-type="pmid">1831223</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bolad</surname><given-names>A</given-names></name><name><surname>Farouk</surname><given-names>SE</given-names></name><name><surname>Israelsson</surname><given-names>E</given-names></name><name><surname>Dolo</surname><given-names>A</given-names></name><name><surname>Doumbo</surname><given-names>OK</given-names></name><name><surname>Nebi&#x000e9;</surname><given-names>I</given-names></name><name><surname>Maiga</surname><given-names>B</given-names></name><name><surname>Kouriba</surname><given-names>B</given-names></name><name><surname>Luoni</surname><given-names>G</given-names></name><name><surname>Sirima</surname><given-names>BS</given-names></name><name><surname>Modiano</surname><given-names>D</given-names></name><name><surname>Berzins</surname><given-names>K</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name></person-group><article-title>Distinct interethnic differences in immunoglobulin G class/subclass and immunoglobulin M antibody responses to malaria antigens but not in immunoglobulin G responses to nonmalarial antigens in sympatric tribes living in West Africa</article-title><source>Scand J Immunol</source><year>2005</year><volume>61</volume><fpage>380</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">15853923</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-3083.2005.01587.x</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Modiano</surname><given-names>D</given-names></name><name><surname>Chiucchiuini</surname><given-names>A</given-names></name><name><surname>Petrarca</surname><given-names>V</given-names></name><name><surname>Sirima</surname><given-names>BS</given-names></name><name><surname>Luoni</surname><given-names>G</given-names></name><name><surname>Perlmann</surname><given-names>H</given-names></name><name><surname>Esposito</surname><given-names>F</given-names></name><name><surname>Coluzzi</surname><given-names>M</given-names></name></person-group><article-title>Humoral response to <italic>Plasmodium falciparum </italic>Pf155/ring-infected erythrocyte surface antigen and Pf332 in three sympatric ethnic groups of Burkina Faso</article-title><source>Am J Trop Med Hyg</source><year>1998</year><volume>58</volume><fpage>220</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">9502607</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Modiano</surname><given-names>D</given-names></name><name><surname>Chiucchiuini</surname><given-names>A</given-names></name><name><surname>Petrarca</surname><given-names>V</given-names></name><name><surname>Sirima</surname><given-names>BS</given-names></name><name><surname>Luoni</surname><given-names>G</given-names></name><name><surname>Roggero</surname><given-names>MA</given-names></name><name><surname>Corradin</surname><given-names>G</given-names></name><name><surname>Coluzzi</surname><given-names>M</given-names></name><name><surname>Esposito</surname><given-names>F</given-names></name></person-group><article-title>Interethnic differences in the humoral response to non-repetitive regions of the <italic>Plasmodium falciparum </italic>circumsporozoite protein</article-title><source>Am J Trop Med Hyg</source><year>1999</year><volume>61</volume><fpage>663</fpage><lpage>667</lpage><pub-id pub-id-type="pmid">10548307</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Modiano</surname><given-names>D</given-names></name><name><surname>Luoni</surname><given-names>G</given-names></name><name><surname>Petrarca</surname><given-names>V</given-names></name><name><surname>Sodiomon Sirima</surname><given-names>B</given-names></name><name><surname>De Luca</surname><given-names>M</given-names></name><name><surname>Simpore</surname><given-names>J</given-names></name><name><surname>Coluzzi</surname><given-names>M</given-names></name><name><surname>Bodmer</surname><given-names>JG</given-names></name><name><surname>Modiano</surname><given-names>G</given-names></name></person-group><article-title>HLA class I in three West African ethnic groups: genetic distances from sub-Saharan and Caucasoid populations</article-title><source>Tissue Antigens</source><year>2001</year><volume>57</volume><fpage>128</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">11260507</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-0039.2001.057002128.x</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Modiano</surname><given-names>D</given-names></name><name><surname>Petrarca</surname><given-names>V</given-names></name><name><surname>Sirima</surname><given-names>BS</given-names></name><name><surname>Bosman</surname><given-names>A</given-names></name><name><surname>Nebi&#x000e9;</surname><given-names>I</given-names></name><name><surname>Diallo</surname><given-names>D</given-names></name><name><surname>Lamizana</surname><given-names>L</given-names></name><name><surname>Esposito</surname><given-names>F</given-names></name><name><surname>Coluzzi</surname><given-names>M</given-names></name></person-group><article-title><italic>Plasmodium falciparum </italic>malaria in sympatric ethnic groups of Burkina Faso, west Africa</article-title><source>Parassitologia</source><year>1995</year><volume>37</volume><fpage>255</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">8778668</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Modiano</surname><given-names>D</given-names></name><name><surname>Petrarca</surname><given-names>V</given-names></name><name><surname>Sirima</surname><given-names>BS</given-names></name><name><surname>Nebi&#x000e9;</surname><given-names>I</given-names></name><name><surname>Diallo</surname><given-names>D</given-names></name><name><surname>Esposito</surname><given-names>F</given-names></name><name><surname>Coluzzi</surname><given-names>M</given-names></name></person-group><article-title>Different response to <italic>Plasmodium falciparum </italic>malaria in west African sympatric ethnic groups</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><fpage>13206</fpage><lpage>13211</lpage><pub-id pub-id-type="pmid">8917569</pub-id><pub-id pub-id-type="doi">10.1073/pnas.93.23.13206</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>JP</given-names></name><name><surname>Nasr</surname><given-names>A</given-names></name><name><surname>Rocca</surname><given-names>KM</given-names></name><name><surname>Troy-Blomberg</surname><given-names>M</given-names></name><name><surname>Elghazali</surname><given-names>G</given-names></name></person-group><article-title>Significant differences in GM allotype frequencies between two sympatric tribes with markedly differential susceptibility to malaria</article-title><source>Parasite immunol</source><year>2007</year><volume>29</volume><fpage>267</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">17430550</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-3024.2007.00938.x</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Modiano</surname><given-names>D</given-names></name><name><surname>Luoni</surname><given-names>G</given-names></name><name><surname>Sirima</surname><given-names>BS</given-names></name><name><surname>Lanfrancotti</surname><given-names>A</given-names></name><name><surname>Petrarca</surname><given-names>V</given-names></name><name><surname>Cruciani</surname><given-names>F</given-names></name><name><surname>Simpore</surname><given-names>J</given-names></name><name><surname>Ciminelli</surname><given-names>BM</given-names></name><name><surname>Foglietta</surname><given-names>E</given-names></name><name><surname>Grisanti</surname><given-names>P</given-names></name><name><surname>Bianco</surname><given-names>I</given-names></name><name><surname>Modiano</surname><given-names>G</given-names></name><name><surname>Coluzzi</surname><given-names>M</given-names></name></person-group><article-title>The lower susceptibility to <italic>Plasmodium falciparum </italic>malaria of Fulani of Burkina Faso (west Africa) is associated with low frequencies of classic malaria-resistance genes</article-title><source>Trans R Soc Trop Med Hyg</source><year>2001</year><volume>95</volume><fpage>149</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">11355545</pub-id><pub-id pub-id-type="doi">10.1016/S0035-9203(01)90141-5</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Creasey</surname><given-names>A</given-names></name><name><surname>Giha</surname><given-names>H</given-names></name><name><surname>Hamad</surname><given-names>AA</given-names></name><name><surname>El Hassan</surname><given-names>IM</given-names></name><name><surname>Theander</surname><given-names>TG</given-names></name><name><surname>Arnot</surname><given-names>DE</given-names></name></person-group><article-title>Eleven years of malaria surveillance in a Sudanese village highlights unexpected variation in individual disease susceptibility and outbreak severity</article-title><source>Parasitol</source><year>2004</year><volume>129</volume><fpage>263</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1017/S0031182004005724</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nasr</surname><given-names>A</given-names></name><name><surname>Elghazali</surname><given-names>G</given-names></name><name><surname>Giha</surname><given-names>H</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Berzins</surname><given-names>K</given-names></name></person-group><article-title>Interethnic differences in carriage of haemoglobin AS and Fcgamma receptor IIa (CD32) genotypes in children living in eastern Sudan</article-title><source>Acta Trop</source><year>2008</year><volume>105</volume><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">18022136</pub-id><pub-id pub-id-type="doi">10.1016/j.actatropica.2007.10.003</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giha</surname><given-names>HA</given-names></name><name><surname>Staalsoe</surname><given-names>T</given-names></name><name><surname>Dodoo</surname><given-names>D</given-names></name><name><surname>Elhassan</surname><given-names>IM</given-names></name><name><surname>Roper</surname><given-names>C</given-names></name><name><surname>Satti</surname><given-names>GM</given-names></name><name><surname>Arnot</surname><given-names>DE</given-names></name><name><surname>Theander</surname><given-names>TG</given-names></name><name><surname>Hviid</surname><given-names>L</given-names></name></person-group><article-title>Nine-year longitudinal study of antibodies to variant antigens on the surface of <italic>Plasmodium falciparum</italic>-infected erythrocytes</article-title><source>Infect Immun</source><year>1999</year><volume>67</volume><fpage>4092</fpage><lpage>4098</lpage><pub-id pub-id-type="pmid">10417178</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamad</surname><given-names>AA</given-names></name><name><surname>El Hassan</surname><given-names>IM</given-names></name><name><surname>El Khalifa</surname><given-names>AA</given-names></name><name><surname>Ahmed</surname><given-names>GI</given-names></name><name><surname>Abdelrahim</surname><given-names>SA</given-names></name><name><surname>Theander</surname><given-names>TG</given-names></name><name><surname>Arnot</surname><given-names>DE</given-names></name></person-group><article-title>Chronic <italic>Plasmodium falciparum </italic>infections in an area of low intensity malaria transmission in the Sudan</article-title><source>Parasitol</source><year>2000</year><volume>120</volume><fpage>447</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1017/S0031182099005818</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Theander</surname><given-names>TG</given-names></name></person-group><article-title>Unstable malaria in Sudan: the influence of the dry season. Malaria in areas of unstable and seasonal transmission. Lessons from Daraweesh</article-title><source>Trans R Soc Trop Med Hyg</source><year>1998</year><volume>92</volume><fpage>589</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">10326097</pub-id><pub-id pub-id-type="doi">10.1016/S0035-9203(98)90775-1</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bereczky</surname><given-names>S</given-names></name><name><surname>Montgomery</surname><given-names>SM</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Rooth</surname><given-names>I</given-names></name><name><surname>Shaw</surname><given-names>MA</given-names></name><name><surname>Farnert</surname><given-names>A</given-names></name></person-group><article-title>Elevated anti-malarial IgE in asymptomatic individuals is associated with reduced risk for subsequent clinical malaria</article-title><source>Int J Parasitol</source><year>2004</year><volume>34</volume><fpage>935</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">15217732</pub-id><pub-id pub-id-type="doi">10.1016/j.ijpara.2004.04.007</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>XM</given-names></name><name><surname>Arepally</surname><given-names>G</given-names></name><name><surname>Poncz</surname><given-names>M</given-names></name><name><surname>McKenzie</surname><given-names>SE</given-names></name></person-group><article-title>Rapid detection of the Fc gamma RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED)</article-title><source>J Immunol Methods</source><year>1996</year><volume>199</volume><fpage>55</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">8960098</pub-id><pub-id pub-id-type="doi">10.1016/S0022-1759(96)00164-0</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perlmann</surname><given-names>H</given-names></name><name><surname>Perlmann</surname><given-names>P</given-names></name><name><surname>Berzins</surname><given-names>K</given-names></name><name><surname>W&#x000e5;hlin</surname><given-names>B</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Hagstedt</surname><given-names>M</given-names></name><name><surname>Andersson</surname><given-names>I</given-names></name><name><surname>Hogh</surname><given-names>B</given-names></name><name><surname>Petersen</surname><given-names>E</given-names></name><name><surname>Bj&#x000f6;rkman</surname><given-names>A</given-names></name></person-group><article-title>Dissection of the human antibody response to the malaria antigen Pf155/RESA into epitope specific components</article-title><source>Immunol Rev</source><year>1989</year><volume>112</volume><fpage>115</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">2481640</pub-id><pub-id pub-id-type="doi">10.1111/j.1600-065X.1989.tb00555.x</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saul</surname><given-names>A</given-names></name><name><surname>Lawrence</surname><given-names>G</given-names></name><name><surname>Allworth</surname><given-names>A</given-names></name><name><surname>Elliott</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Rzepczyk</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>LB</given-names></name><name><surname>Taylor</surname><given-names>D</given-names></name><name><surname>Eisen</surname><given-names>DP</given-names></name><name><surname>Irving</surname><given-names>DO</given-names></name><name><surname>Pye</surname><given-names>D</given-names></name><name><surname>Crewther</surname><given-names>PE</given-names></name><name><surname>Hodder</surname><given-names>AN</given-names></name><name><surname>Murphy</surname><given-names>VJ</given-names></name><name><surname>Anders</surname><given-names>RF</given-names></name></person-group><article-title>A human phase 1 vaccine clinical trial of the <italic>Plasmodium falciparum </italic>malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>3076</fpage><lpage>3083</lpage><pub-id pub-id-type="pmid">15811655</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.09.040</pub-id></citation></ref><ref id="B25"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Vasconselos</surname><given-names>N</given-names></name></person-group><article-title>Vaccine development strategies applied to the <italic>Plasmodium falciparum </italic>malaria antigen Pf332</article-title><source>PhD thesis</source><year>2006</year><publisher-name>Stockholm University, Wenner-Gren Institute</publisher-name></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rascu</surname><given-names>A</given-names></name><name><surname>Repp</surname><given-names>R</given-names></name><name><surname>Westerdaal</surname><given-names>NA</given-names></name><name><surname>Kalden</surname><given-names>JR</given-names></name><name><surname>Winkel</surname><given-names>JG van de</given-names></name></person-group><article-title>Clinical relevance of Fc gamma receptor polymorphisms</article-title><source>Ann N Y Acad Sci</source><year>1997</year><volume>815</volume><fpage>282</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">9186665</pub-id><pub-id pub-id-type="doi">10.1111/j.1749-6632.1997.tb52070.x</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Israelsson</surname><given-names>E</given-names></name><name><surname>Vafa</surname><given-names>M</given-names></name><name><surname>Maiga</surname><given-names>B</given-names></name><name><surname>Lysen</surname><given-names>A</given-names></name><name><surname>Iriemenam</surname><given-names>NC</given-names></name><name><surname>Dolo</surname><given-names>A</given-names></name><name><surname>Doumbo</surname><given-names>OK</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Berzins</surname><given-names>K</given-names></name></person-group><article-title>Differences in Fc gamma receptor IIa genotypes and IgG subclass pattern of anti-malarial antibodies between sympatric ethnic groups in Mali</article-title><source>Malar J</source><year>2008</year><volume>7</volume><fpage>175</fpage><pub-id pub-id-type="pmid">18793404</pub-id><pub-id pub-id-type="doi">10.1186/1475-2875-7-175</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooke</surname><given-names>GS</given-names></name><name><surname>Aucan</surname><given-names>C</given-names></name><name><surname>Walley</surname><given-names>AJ</given-names></name><name><surname>Segal</surname><given-names>S</given-names></name><name><surname>Greenwood</surname><given-names>BM</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><name><surname>Hill</surname><given-names>AV</given-names></name></person-group><article-title>Association of Fcgamma receptor IIa (CD32) polymorphism with severe malaria in West Africa</article-title><source>Am J Trop Med Hyg</source><year>2003</year><volume>69</volume><fpage>565</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">14740869</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>YP</given-names></name><name><surname>Nahlen</surname><given-names>BL</given-names></name><name><surname>Kariuki</surname><given-names>S</given-names></name><name><surname>Urdahl</surname><given-names>KB</given-names></name><name><surname>McElroy</surname><given-names>PD</given-names></name><name><surname>Roberts</surname><given-names>JM</given-names></name><name><surname>Lal</surname><given-names>AA</given-names></name></person-group><article-title>Fcgamma receptor IIa (CD32) polymorphism is associated with protection of infants against high-density <italic>Plasmodium falciparum </italic>infection. VII. Asembo Bay Cohort Project</article-title><source>J Infect Dis</source><year>2001</year><volume>184</volume><fpage>107</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">11398118</pub-id><pub-id pub-id-type="doi">10.1086/320999</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ntoumi</surname><given-names>F</given-names></name><name><surname>Flori</surname><given-names>L</given-names></name><name><surname>Mayengue</surname><given-names>PI</given-names></name><name><surname>Matondo Maya</surname><given-names>DW</given-names></name><name><surname>Issifou</surname><given-names>S</given-names></name><name><surname>Deloron</surname><given-names>P</given-names></name><name><surname>Lell</surname><given-names>B</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name><name><surname>Rihet</surname><given-names>P</given-names></name></person-group><article-title>Influence of carriage of hemoglobin AS and the Fc gamma receptor IIa-R131 allele on levels of immunoglobulin G2 antibodies to <italic>Plasmodium falciparum </italic>merozoite antigens in Gabonese children</article-title><source>J Infect Dis</source><year>2005</year><volume>192</volume><fpage>1975</fpage><lpage>1980</lpage><pub-id pub-id-type="pmid">16267770</pub-id><pub-id pub-id-type="doi">10.1086/497611</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Omi</surname><given-names>K</given-names></name><name><surname>Ohashi</surname><given-names>J</given-names></name><name><surname>Patarapotikul</surname><given-names>J</given-names></name><name><surname>Hananantachai</surname><given-names>H</given-names></name><name><surname>Naka</surname><given-names>I</given-names></name><name><surname>Looareesuwan</surname><given-names>S</given-names></name><name><surname>Tokunaga</surname><given-names>K</given-names></name></person-group><article-title>Fc gamma receptor IIA and IIIB polymorphisms are associated with susceptibility to cerebral malaria</article-title><source>Parasitol Int</source><year>2002</year><volume>51</volume><fpage>361</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">12421634</pub-id><pub-id pub-id-type="doi">10.1016/S1383-5769(02)00040-5</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nasr</surname><given-names>A</given-names></name><name><surname>Iriemenam</surname><given-names>NC</given-names></name><name><surname>Troye-Blomberg</surname><given-names>M</given-names></name><name><surname>Giha</surname><given-names>HA</given-names></name><name><surname>Balogun</surname><given-names>HA</given-names></name><name><surname>Osman</surname><given-names>OF</given-names></name><name><surname>Montgomery</surname><given-names>SM</given-names></name><name><surname>ElGhazali</surname><given-names>G</given-names></name><name><surname>Berzins</surname><given-names>K</given-names></name></person-group><article-title>Fc gamma receptor IIa (CD32) polymorphism and antibody responses to asexual blood-stage antigens of <italic>Plasmodium falciparum </italic>malaria in Sudanese patients</article-title><source>Scand J Immunol</source><year>2007</year><volume>66</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">17587350</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-3083.2007.01947.x</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Mishra</surname><given-names>SK</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Patibandla</surname><given-names>PK</given-names></name><name><surname>Mallick</surname><given-names>PK</given-names></name><name><surname>Sharma</surname><given-names>SK</given-names></name><name><surname>Mohanty</surname><given-names>S</given-names></name><name><surname>Pati</surname><given-names>SS</given-names></name><name><surname>Mishra</surname><given-names>SK</given-names></name><name><surname>Ramteke</surname><given-names>BK</given-names></name><name><surname>Bhatt</surname><given-names>RM</given-names></name><name><surname>Joshi</surname><given-names>H</given-names></name><name><surname>Dash</surname><given-names>AP</given-names></name><name><surname>Ahuja</surname><given-names>RC</given-names></name><name><surname>Awasthi</surname><given-names>S</given-names></name><name><surname>Consortium</surname><given-names>IG</given-names></name><name><surname>Venkatesh</surname><given-names>V</given-names></name><name><surname>Habib</surname><given-names>S</given-names></name></person-group><article-title>Polymorphisms of TNF-enhancer and gene for FcgammaRIIa correlate with the severity of falciparum malaria in the ethnically diverse Indian population</article-title><source>Malar J</source><year>2008</year><volume>7</volume><fpage>13</fpage><pub-id pub-id-type="pmid">18194515</pub-id><pub-id pub-id-type="doi">10.1186/1475-2875-7-13</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamad</surname><given-names>AA</given-names></name><name><surname>Nugud Ael</surname><given-names>H</given-names></name><name><surname>Arnot</surname><given-names>DE</given-names></name><name><surname>Giha</surname><given-names>HA</given-names></name><name><surname>Abdel-Muhsin</surname><given-names>AM</given-names></name><name><surname>Satti</surname><given-names>GM</given-names></name><name><surname>Theander</surname><given-names>TG</given-names></name><name><surname>Creasey</surname><given-names>AM</given-names></name><name><surname>Babiker</surname><given-names>HA</given-names></name><name><surname>Elnaiem</surname><given-names>DE</given-names></name></person-group><article-title>A marked seasonality of malaria transmission in two rural sites in eastern Sudan</article-title><source>Acta Trop</source><year>2002</year><volume>83</volume><fpage>71</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">12062795</pub-id><pub-id pub-id-type="doi">10.1016/S0001-706X(02)00059-1</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Groux</surname><given-names>H</given-names></name><name><surname>Gysin</surname><given-names>J</given-names></name></person-group><article-title>Opsonization as an effector mechanism in human protection against asexual blood stages of <italic>Plasmodium falciparum</italic>: functional role of IgG subclasses</article-title><source>Res Immunol</source><year>1990</year><volume>141</volume><fpage>529</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">1704637</pub-id><pub-id pub-id-type="doi">10.1016/0923-2494(90)90021-P</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tebo</surname><given-names>AE</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name><name><surname>Luty</surname><given-names>AJ</given-names></name></person-group><article-title>Fc gamma receptor-mediated phagocytosis of <italic>Plasmodium falciparum</italic>-infected erythrocytes in vitro</article-title><source>Clin Exp Immunol</source><year>2002</year><volume>130</volume><fpage>300</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">12390319</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2249.2002.01972.x</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bredius</surname><given-names>RG</given-names></name><name><surname>de Vries</surname><given-names>CE</given-names></name><name><surname>Troelstra</surname><given-names>A</given-names></name><name><surname>van Alphen</surname><given-names>L</given-names></name><name><surname>Weening</surname><given-names>RS</given-names></name><name><surname>Winkel</surname><given-names>JG van de</given-names></name><name><surname>Out</surname><given-names>TA</given-names></name></person-group><article-title>Phagocytosis of Staphylococcus aureus and Haemophilus influenzae type B opsonized with polyclonal human IgG1 and IgG2 antibodies. Functional hFc gamma RIIa polymorphism to IgG2</article-title><source>J Immunol</source><year>1993</year><volume>151</volume><fpage>1463</fpage><lpage>1472</lpage><pub-id pub-id-type="pmid">8335940</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parren</surname><given-names>PW</given-names></name><name><surname>Warmerdam</surname><given-names>PA</given-names></name><name><surname>Boeije</surname><given-names>LC</given-names></name><name><surname>Arts</surname><given-names>J</given-names></name><name><surname>Westerdaal</surname><given-names>NA</given-names></name><name><surname>Vlug</surname><given-names>A</given-names></name><name><surname>Capel</surname><given-names>PJ</given-names></name><name><surname>Aarden</surname><given-names>LA</given-names></name><name><surname>Winkel</surname><given-names>JG van de</given-names></name></person-group><article-title>On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2</article-title><source>J Clin Invest</source><year>1992</year><volume>90</volume><fpage>1537</fpage><lpage>1546</lpage><pub-id pub-id-type="pmid">1401085</pub-id><pub-id pub-id-type="doi">10.1172/JCI116022</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salmon</surname><given-names>JE</given-names></name><name><surname>Edberg</surname><given-names>JC</given-names></name><name><surname>Brogle</surname><given-names>NL</given-names></name><name><surname>Kimberly</surname><given-names>RP</given-names></name></person-group><article-title>Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function</article-title><source>J Clin Invest</source><year>1992</year><volume>89</volume><fpage>1274</fpage><lpage>1281</lpage><pub-id pub-id-type="pmid">1532589</pub-id><pub-id pub-id-type="doi">10.1172/JCI115712</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>LA</given-names></name><name><surname>Feldman</surname><given-names>RG</given-names></name><name><surname>Voorhorst-Ogink</surname><given-names>MM</given-names></name><name><surname>de Haas</surname><given-names>M</given-names></name><name><surname>Rijkers</surname><given-names>GT</given-names></name><name><surname>Capel</surname><given-names>PJ</given-names></name><name><surname>Zegers</surname><given-names>BJ</given-names></name><name><surname>Winkel</surname><given-names>JG van de</given-names></name></person-group><article-title>Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils</article-title><source>Infect Immun</source><year>1995</year><volume>63</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">7806386</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bouharoun-Tayoun</surname><given-names>H</given-names></name><name><surname>Druilhe</surname><given-names>P</given-names></name></person-group><article-title><italic>Plasmodium falciparum </italic>malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity</article-title><source>Infect Immun</source><year>1992</year><volume>60</volume><fpage>1473</fpage><lpage>1481</lpage><pub-id pub-id-type="pmid">1548071</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aucan</surname><given-names>C</given-names></name><name><surname>Traore</surname><given-names>Y</given-names></name><name><surname>Tall</surname><given-names>F</given-names></name><name><surname>Nacro</surname><given-names>B</given-names></name><name><surname>Traore-Leroux</surname><given-names>T</given-names></name><name><surname>Fumoux</surname><given-names>F</given-names></name><name><surname>Rihet</surname><given-names>P</given-names></name></person-group><article-title>High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to <italic>Plasmodium falciparum </italic>malaria</article-title><source>Infect Immun</source><year>2000</year><volume>68</volume><fpage>1252</fpage><lpage>1258</lpage><pub-id pub-id-type="pmid">10678934</pub-id><pub-id pub-id-type="doi">10.1128/IAI.68.3.1252-1258.2000</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>RR</given-names></name><name><surname>Smith</surname><given-names>DB</given-names></name><name><surname>Robinson</surname><given-names>VJ</given-names></name><name><surname>McBride</surname><given-names>JS</given-names></name><name><surname>Riley</surname><given-names>EM</given-names></name></person-group><article-title>Human antibody response to <italic>Plasmodium falciparum </italic>merozoite surface protein 2 is sero-group specific and predominantly of the immunoglobulin G3 subclass</article-title><source>Infect Immun</source><year>1995</year><volume>63</volume><fpage>4382</fpage><lpage>4388</lpage><pub-id pub-id-type="pmid">7591074</pub-id></citation></ref></ref-list></back></article> 